Display options
Cite
Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics. 2013;5(3):457-71doi: 10.3390/pharmaceutics5030457.
Mignet, N., Seguin, J., & Chabot, G. G. (2013). Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics, 5(3), 457-71. https://doi.org/10.3390/pharmaceutics5030457
Mignet, Nathalie, et al. "Bioavailability of polyphenol liposomes: a challenge ahead." Pharmaceutics vol. 5,3 (2013): 457-71. doi: https://doi.org/10.3390/pharmaceutics5030457
Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. Pharmaceutics. 2013 Sep 17;5(3):457-71. doi: 10.3390/pharmaceutics5030457. PMID: 24300518; PMCID: PMC3836625.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2013 Sep 17;5(3):457-71. doi: 10.3390/pharmaceutics5030457.

Bioavailability of polyphenol liposomes: a challenge ahead.

Pharmaceutics

Nathalie Mignet, Johanne Seguin, Guy G Chabot

Affiliations

  1. Chemical, Genetic and Imaging Pharmacology Laboratory (CNRS UMR 8151, INSERM U1022), Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, Chimie-ParisTech, 4 avenue de l'Observatoire, Paris F-75006, France. [email protected].

PMID: 24300518 PMCID: PMC3836625 DOI: 10.3390/pharmaceutics5030457

Abstract

Dietary polyphenols, including flavonoids, have long been recognized as a source of important molecules involved in the prevention of several diseases, including cancer. However, because of their poor bioavailability, polyphenols remain difficult to be employed clinically. Over the past few years, a renewed interest has been devoted to the use of liposomes as carriers aimed at increasing the bioavailability and, hence, the therapeutic benefits of polyphenols. In this paper, we review the causes of the poor bioavailability of polyphenols and concentrate on their liposomal formulations, which offer a means of improving their pharmacokinetics and pharmacodynamics. The problems linked to their development and their potential therapeutic advantages are reviewed. Future directions for liposomal polyphenol development are suggested.

References

  1. Biosci Biotechnol Biochem. 2004 Aug;68(8):1743-7 - PubMed
  2. J Drug Target. 2011 Sep;19(8):709-18 - PubMed
  3. Int J Cancer. 2009 Jul 1;125(1):1-8 - PubMed
  4. Int J Pharm. 2006 Feb 3;308(1-2):140-8 - PubMed
  5. Cancer Prev Res (Phila). 2011 Aug;4(8):1158-71 - PubMed
  6. J Agric Food Chem. 2009 Oct 14;57(19):9141-6 - PubMed
  7. J Nutr. 2000 Aug;130(8S Suppl):2073S-85S - PubMed
  8. Int J Pharm. 2013 Feb 28;444(1-2):146-54 - PubMed
  9. Nat Prod Rep. 1994 Jan;11(1):41-66 - PubMed
  10. J Nutr. 2006 Sep;136(9):2368-73 - PubMed
  11. Mol Biotechnol. 2013 Sep;55(1):78-86 - PubMed
  12. Am J Clin Nutr. 2004 May;79(5):727-47 - PubMed
  13. J Dermatol Sci. 2006 May;42(2):101-9 - PubMed
  14. Int J Pharm. 2008 Nov 3;363(1-2):183-91 - PubMed
  15. Int J Pharm. 2011 Sep 20;416(2):433-42 - PubMed
  16. Nutrients. 2010 Dec;2(12):1231-46 - PubMed
  17. Int J Nanomedicine. 2012;7:49-60 - PubMed
  18. Drugs. 1993 Jan;45(1):15-28 - PubMed
  19. Yao Xue Xue Bao. 2007 Aug;42(8):886-91 - PubMed
  20. Curr Opin Plant Biol. 2002 Jun;5(3):218-23 - PubMed
  21. Free Radic Biol Med. 1996;20(7):933-56 - PubMed
  22. Cancer Prev Res (Phila). 2011 Sep;4(9):1419-25 - PubMed
  23. Nutrition. 2002 Jan;18(1):75-81 - PubMed
  24. Pharmacol Ther. 2002 Nov-Dec;96(2-3):67-202 - PubMed
  25. Life Sci. 1999;65(4):337-53 - PubMed
  26. J Control Release. 2002 Nov 7;84(1-2):27-37 - PubMed
  27. Int J Pharm. 2012 Feb 14;423(1):69-76 - PubMed
  28. Clin Cancer Res. 2006 May 15;12(10):3193-9 - PubMed
  29. Chem Biol Drug Des. 2008 Jan;71(1):3-7 - PubMed
  30. Cancer. 2005 Sep 15;104(6):1322-31 - PubMed
  31. Int J Pharm. 2013 Aug 30;453(1):225-32 - PubMed
  32. J Pharmacol Exp Ther. 2003 Mar;304(3):1228-35 - PubMed
  33. PLoS One. 2012;7(8):e41438 - PubMed
  34. Biochim Biophys Acta. 1996 May 22;1281(1):31-7 - PubMed
  35. Mol Cancer Ther. 2007 Apr;6(4):1276-82 - PubMed
  36. Int J Mol Sci. 2010 Mar 31;11(4):1321-42 - PubMed
  37. Int J Nanomedicine. 2006;1(3):297-315 - PubMed
  38. Biochemistry. 1996 Feb 27;35(8):2521-5 - PubMed
  39. Crit Rev Clin Lab Sci. 2011 Sep-Dec;48(5-6):197-216 - PubMed
  40. Cancer Chemother Pharmacol. 2007 Jul;60(2):171-7 - PubMed
  41. Expert Opin Biol Ther. 2001 Nov;1(6):923-47 - PubMed
  42. Int J Pharm. 2006 Aug 2;318(1-2):55-61 - PubMed
  43. Am J Clin Nutr. 2001 Oct;74(4):418-25 - PubMed
  44. Int J Pharm. 2006 Aug 17;319(1-2):121-9 - PubMed
  45. Chem Pharm Bull (Tokyo). 2007 May;55(5):800-3 - PubMed
  46. Langmuir. 2011 Dec 6;27(23):14112-7 - PubMed
  47. Ann Oncol. 2001 Feb;12(2):245-8 - PubMed
  48. Int J Nanomedicine. 2012;7:271-80 - PubMed
  49. Int J Pharm. 2009 Sep 11;379(2):270-7 - PubMed
  50. J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2950-8 - PubMed
  51. Eur J Pharm Sci. 2005 Nov;26(3-4):251-65 - PubMed
  52. Pak J Biol Sci. 2007 May 15;10(10):1643-8 - PubMed
  53. J Nutr. 2008 Aug;138(8):1561S-1566S - PubMed
  54. Int J Pharm. 2012 May 10;427(2):452-9 - PubMed
  55. Biosci Biotechnol Biochem. 2008 Dec;72(12):3289-92 - PubMed
  56. Int J Pharm. 2006 Aug 17;319(1-2):162-8 - PubMed
  57. Acta Pharmacol Sin. 2011 Jul;32(7):973-80 - PubMed
  58. J Drug Deliv. 2011;2011:591325 - PubMed
  59. Mol Pharm. 2007 Nov-Dec;4(6):826-32 - PubMed
  60. J Agric Food Chem. 2007 Nov 28;55(24):9986-92 - PubMed
  61. Toxins (Basel). 2010 Jan;2(1):128-62 - PubMed
  62. J Agric Food Chem. 2002 Jun 5;50(12):3453-7 - PubMed
  63. Colloids Surf B Biointerfaces. 2013 Oct 1;110:296-304 - PubMed
  64. J Pharm Biomed Anal. 2004 Feb 4;34(2):333-9 - PubMed
  65. Int J Cancer. 2007 Nov 15;121(10):2225-32 - PubMed
  66. Clin Dev Immunol. 2005 Mar;12(1):19-25 - PubMed
  67. Anticancer Agents Med Chem. 2009 Feb;9(2):138-61 - PubMed
  68. Drug Deliv. 2002 Jul-Sep;9(3):181-5 - PubMed
  69. Br J Cancer. 2003 Oct 6;89(7):1255-9 - PubMed
  70. J Drug Target. 2005 Jan;13(1):19-27 - PubMed

Publication Types